Press Releases
Onconova Presents Positive Clinical Trial Results for Radiation Injury Protector Ex-RAD
Onconova Therapeutics, Inc. today announced positive human safety, tolerability, and pharmacokinetic data from three clinical trials of Ex-RAD(recilisib sodium, ON 01210.Na), a novel radioprotectant...
Press Releases
Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance Agreement
Sanofi and Bristol-Myers Squibb Company today announced they have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in...
Press Releases
CiToxLAB Group announces a 34 per cent revenue increase for the first half of 2012
CiToxLAB Group, a leading CRO in the field of non-clinical research, announces today that the group’s consolidated first half 2012 revenues reached EUR 37.2M...
Press Releases
Endo Tools Therapeutics completes first-in-human cases with its Endomina triangulation platform
Endo Tools Therapeutics, a developer of advanced, minimally-invasive medical devices to treat obesity, digestive tract tumors and type II diabetes, announces today the completion...
Press Releases
AIBioTech Expands Bioorganic Chemistry Platform
AIBioTech is quickly gaining ground in the niche market of custom synthesis of small molecules, including molecules which contain stable isotopes of particular atoms....
Press Releases
Biophytis will use funds to continue development of its nutraceuticals pipeline and to develop drug candidates derived from nutraceutical active substances for the treatment...
Biophytis, a research company in health and nutrition focusing on metabolic disorders and age-related diseases, announces today that it has raised EUR two million...
Press Releases
Impax Laboratories Announces Settlement of Litigation Relating to CONCERTA®
Impax Laboratories, Inc.today announced that it and Teva Pharmaceuticals USA, Inc. have reached agreement with Janssen Pharmaceuticals, Inc. and ALZA Corporation (together, “ALZA”) to...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.